Journal of Clinical Endocrinology & Metabolism Vol. 63, No. 2 389-393 doi:10.1210/jcem-63-2-389 Copyright © 1986 by the Endocrine Society. Effect of Cholinergic Muscarinic Receptor Blockade on Human Growth Hormone(GH)-Releasing Hormone-(l-44)-Induced GH Secretion in Acromegaly and Type I Diabetes MellitusP. PIETSCHMANN, G. SCHERNTHANER and A. LUGERDepartment of Medicine II, Division of Metabolism and Endocrinology, University of Vienna Vienna, Austria Address all correspondence and requests for reprints to: Univ. Doz. Dr. G. Schernthaner, Department of Medicine II, Division of Metabolism and Endocrinology, University of Vienna, Garnisongasse 13, A-1090 Vienna, Austria. In 10 patients with type I diabetes mellitus, 9 acromegalic patients, and 8 normal subjects, serum GH levels after an iv injection of 1 µg/kg BW human GH-releasing hormone-(l-44) (GHRH) with and without cholinergic muscarinic receptor blockade (1 mg atropine, im, 15 min before GHRH) were measured. The GH increase after GHRH treatment in type I diabetic patients did not differ significantly from that in normal subjects. Pretreatment with atropine almost completely blocked the GH response to GHRH in patients with type I diabetes and normal subjects, but did not suppress the GH response to GHRH in acromegalic patients. These data indicate that cholinergic muscarinic receptors modulate GH secretion in normal man as well as in patients with type I diabetes mellitus, whereas acromegalic patients have a defect of cholinergic control of GH secretion. Received December 12, 1985. This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||